ArticleEuropean heart journal2018
Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank.
Article in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Clinical question: Is systemic inflammation associated with right ventricular myocardial work efficiency, quality of life, and adiposity in adults with repaired tetralogy of Fallot?International journal of cardiology. Congenital heart disease · 2026Article
- Cardiorenal Biomarkers and Cerebrovascular Risk in Patients with Congenital Heart Disease.Journal of clinical medicine · 2026Article
- The association between systemic immune-inflammatory index and cardiac biomarkers among US population: a cross-sectional study.European journal of medical research · 2025Article
- Circulating Biomarkers in Failing Fontan Circulation: Current Evidence and Future Directions.Journal of cardiovascular development and disease · 2025Review
- Pathophysiology of endothelial dysfunction in Fontan circulation: from bench to bedside and back again.Angiogenesis · 2025Review
- Systemic Changes in Adults With a Fontan Circulation: Insights From the Plasma Proteome.Journal of the American Heart Association · 2025Article
- Role of MMP-2, MMP-9, TIMP-1, and TIMP-2 in children with ventricular septal defect.Biomolecules & biomedicine · 2025Article
- Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures.Nature reviews. Cardiology · 2025Review
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
- Subpulmonary ventricular function and inflammation are related to clinical heart failure in patients with a systemic right ventricle.International journal of cardiology. Congenital heart disease · 2024Article
- Association of life's essential 8 with mortality among the individuals with cardiovascular disease.Scientific reports · 2024Article
- High Prevalence of Abnormal Hemoglobin A1c in the Adolescent and Young Adult Fontan Population.Pediatric cardiology · 2024Article
- C-Reactive Protein and Long-Term Prognosis in Adult Patients with Congenital Heart Disease.Journal of clinical medicine · 2024Article
- Acquired Cardiovascular Diseases in Patients with Pulmonary Hypertension Due to Congenital Heart Disease: A Case Report.Medicina (Kaunas, Lithuania) · 2024Article
- Biological Age in Congenital Heart Disease-Exploring the Ticking Clock.Journal of cardiovascular development and disease · 2023Review
- Childhood Obesity and Congenital Heart Disease: A Lifelong Struggle.Journal of clinical medicine · 2023Review
- NT-proBNP Is a Predictor of Mortality in Adults with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.Journal of clinical medicine · 2023Article
- Sex-Specific Thresholds for Cardiac Biomarkers-We Need to Move Forward.Reviews in cardiovascular medicine · 2023Review
- The therapeutic potential of sphingolipids for cardiovascular diseases.Frontiers in cardiovascular medicine · 2023Review
- Serum C reactive protein and procalcitonin are valuable predictors of coronary heart disease and poor prognosis in the elderly.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Aims: Despite the well-defined association of high-sensitivity hsCRP with cardiovascular outcomes in apparently healthy adults and those with acquired heart disease, the relevance of this inflammatory marker in adults with congenital heart disease (ACHD) remains unclear. We aimed to examine the clinical correlates and prognostic value of high-sensitivity C-reactive protein levels in ACHD. Methods and results: We conducted a prospective cohort study of (n = 707) outpatient ACHD (age 39 ± 14 years, 49% women), enrolled mainly at a referral centre, who had serum hsCRP measured in conjunction with a clinical assessment between 2012 and 2016. We analysed clinical correlates of hsCRP and its association with adverse events including the primary combined outcome of all-cause mortality or non-elective cardiovascular hospitalization. Higher hsCRP was strongly associated with measures of functional status including New York Heart Association class and peak V̇O2, and with comorbidities such as atrial arrhythmia. During average follow-up of 815 ± 536 days, 114 patients (16%) experienced the primary outcome, including 29 deaths. Having elevated hsCRP, in the highest (≥2.98 mg/L) compared with the lower three quartiles, conferred increased risk for the primary outcome [30.5% vs. 11.3%, adjusted hazard ratio (HR) = 2.00, 95% confidence interval (CI) 1.35-2.97; P = 0.0006] and all-cause mortality (11.9% vs. 1.5%, adjusted HR = 4.23, 95% CI 1.87-9.59; P = 0.0006). Elevated hsCRP was associated with adverse outcomes across ACHD subgroups and other patient characteristics. Conclusion: Adults with congenital heart disease with elevated hsCRP have not only worse functional status and exercise capacity, but also greater risk for death or non-elective cardiovascular hospitalization. Further study is warranted to characterize the role of inflammation in the pathophysiology of ACHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.